CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial

(MedPage Today) -- CHICAGO -- Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of patients with relapsed or refractory...
Source
MedPage Today
Opens original article in a new tab



